NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gene therapy breakthrough for wet AMD? new trial underway
Disease control OngoingThis study tests a gene therapy called LX102 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The goal is to see if it is safe and can improve or maintain eyesight, possibly reducing the need for frequent eye injections. About 50 adults…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated May 26, 2026 11:06 UTC
-
Gene therapy for wet AMD: how do eyes hold up years later?
Disease control OngoingThis study follows 23 people who received a single dose of ADVM-022 gene therapy for wet age-related macular degeneration (AMD). Researchers are checking long-term safety and whether vision improvements last. Participants are observed over time without receiving additional treatm…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 26, 2026 11:05 UTC
-
New eye drug faricimab tracked in 1,000 chinese patients for Long-Term results
Disease control OngoingThis study follows about 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will track vision changes, eye thickness, and treatment patterns over one year to see how …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 11:04 UTC
-
Which wet AMD injection lasts longer? major study pits avastin against eylea
Disease control OngoingThis study compares two drugs, bevacizumab (Avastin) and aflibercept (Eylea), given as eye injections for wet age-related macular degeneration (AMD). About 402 adults aged 50 and older with wet AMD will receive one of the two drugs for two years. The goal is to see which drug req…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated May 26, 2026 11:02 UTC
-
Higher-Dose eye injection studied for two leading causes of vision loss
Disease control OngoingThis study tests a higher dose of the drug aflibercept (8 mg) given as an eye injection every 4 weeks. It includes about 1,100 adults with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME) who have already received anti-VEGF treatment. The main goal is t…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New eye drug ASKG712 enters human testing for blinding disease
Disease control OngoingThis early-stage study tests a new medicine called ASKG712, given as an eye injection, for people with wet age-related macular degeneration (a common cause of vision loss). The main goal is to check safety and how the body handles the drug. About 56 adults aged 50 to 80 with acti…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
One-Time gene therapy could free wet AMD patients from lifelong eye injections
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New syringe vs vial: which is safer for eye injections?
Symptom relief OngoingThis study tests whether giving ONS-5010 (a bevacizumab eye injection) from a pre-filled syringe is as safe as using a standard vial. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will take part. The main goal…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Symptom relief
Last updated May 20, 2026 11:54 UTC
-
Massive eye study tracks Real-World drug performance
Knowledge-focused OngoingThis study is gathering long-term information from about 6,000 people receiving Roche eye medications for conditions like age-related macular degeneration and diabetic eye disease. The goal is to see how well these treatments work in everyday medical practice, not in a controlled…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated May 26, 2026 11:05 UTC